Intervention: Tilarginine
Trial phase: Phase 4
SMILES: CNC(=N)NCCC[C@H](N)C(=O)O
Sex: All
Age groups: Adult | Older Adult
Healthy volunteers: No
Participants at risk: 72
Group description: Targin(Oxycodone/Naloxone)

Targin: Single arm for Targin
Eligibility criteria:
Inclusion Criteria:

Male or female ≥ 20 and <80 years of age
Patients who has diagnosed as Chemotherapy-Induced Peripheral Neuropathy by investigator's judgment
Patient who are receiving pregabalin for the treatment of Chemotherapy- Induced Peripheral Neuropathy
Patients who have moderate to severe pain intensity which is not controlled with 300mg of pregabalin per day for at least 1 week: NRS ≥ 4
Patients who need opioid combination treatment with existing pregabalin treatment
Naïve patients for strong opioid (Naïve patient defined as who did not treated for 90 days)
Patients who signed a written informed consent form

Exclusion Criteria:

Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant. UNLESS they are:

women whose partners have been sterilized by vasectomy or other means
two birth control methods. The two methods can be a double barrier method or a barrier method plus a hormonal method. Adequate barrier methods of contraception include: diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge or spermicidal. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or (Progest - progesterone) progestational agent.
Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive urine pregnancy test
Patients with known hypersensitivity to Oxycodone or Naloxone or to any of the excipients
Patients with severe respiratory depression with hypoxia and/or hypercapnia
Patients with severe chronic obstructive pulmonary disease
Patients with cor pulmonale
Patients with severe bronchial asthma
Patients with non-opioid induced paralytic ileus
Patients with moderate to severe hepatic impairment
Targin product contains lactose. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take
Abnormal aspartate aminotransferase (AST; SGOT), alanine aminotransferase (ALT; SGPT), or alkaline phosphatase levels (>2.5 times the upper limit of normal, it is allowed >5 times the upper limit of normal in case of transition in liver) or an abnormal total bilirubin and/or creatinine level(s) (greater than 1.5 times the upper limit of normal), gamma glutamyl transpeptidase (GGT or GGTP) ≥ 3 times the upper limit of normal
Patients with uncontrolled seizures
Requiring interventional treatment for pain such as neural blockade procedure or regional infusion
Patients with increased intracranial pressure
In the investigator's opinion, subjects who are receiving hypnotics or other central nervous system (CNS) depressants that may pose a risk of additional CNS depression with opioid study medication
Patients with myxoedema, not adequately treated hypothyroidism or Addison's disease
Patients receiving opioid substitution therapy for opioid addiction (e.g. methadone or buprenorphine)
Clinically significant impairment of cardiovascular, respiratory and renal function
Major surgery within 1 month prior to screening or planned surgery
Chemotherapy or radiotherapy within 2 weeks prior to the screening visit, or planned chemotherapy or radiotherapy during the study period.
Mainly pain originated other than Chemotherapy-Induced Peripheral Neuropathy
Patients with diabetic neuropathy
With a disability that may prevent the patient from completing all study requirements and in particular, interfere with 24hrs pain intensity score
Patients known to have, or suspected of having a history of drug abuse
Patients with history of opioid or drug dependence
Any situation where opioids are contraindicated
Having used other investigational drugs at the time of enrollment, or within 30 days of enrollment